ReviewDer Nervenarzt2013
[Neuromyelitis optica].
Review in Der Nervenarzt, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 64 citations in OpenAlex.
- Identification of geraldol as an inhibitor of aquaporin‑4 binding by NMO‑IgG.Molecular medicine reports · 2020Article
- The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders.Frontiers in neurology · 2020Article
- Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.The EPMA journal · 2018Review
- [Neuromyelitis optica spectrum disorder and pregnancy].Der Nervenarzt · 2018Review
- Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.The EPMA journal · 2018Review
- [Optical coherence tomography in neuromyelitis optica spectrum disorders].Der Nervenarzt · 2017Review
- [Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].Der Nervenarzt · 2014Review
- Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.Journal of neuroinflammation · 2014Article
- Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Clinical and experimental immunology · 2014Review
- [Ultrahigh field MRI in context of neurological diseases].Der Nervenarzt · 2014Review
- Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.Brain pathology (Zurich, Switzerland) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of serum autoantibodies against the astrocytic water channel aquaporin-4 (AQP4) as a biomarker of neuromyelitis optica (NMO, Devic syndrome) has revolutionized our understanding of this rare immune-mediated clinical entity and has provided a rationale for the use of therapeutic strategies targeting the humoral effector arm of autoimmune responses. This article reviews the clinical features of NMO and highlights recent findings that have elucidated how antibodies and T cells with specificity for AQP4 may be involved in the pathophysiology of the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.